Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis CThursday, 26 July 2018To what extent can R&D incentives, competition and other factors facilitate access to highly valuable and costly pharmaceutical innovations? Read more »
Presentations from AES and PROMs Summer 2018Tuesday, 24 July 2018OHE staff recently attended AES and PROMs Summer 2018 conferences. In this blog post, we share a selection of our presentations. Read more »
OHE’s Paula Lorgelly Elected as HESG Joint National OrganiserMonday, 23 July 2018Paula Lorgelly and Bruce Hollingsworth (Lancaster University) have taken the role of joint National Organisers for the Health Economists’ Study Group. Read more »
How Much Should Society Pay for a New Orphan Drug? A Contribution to this Debate is now Available in a New OHE Research PaperWednesday, 18 July 2018What would be the price for an orphan drug that generate rates of return no greater/smaller than the industry average? Is it reasonable? Read more »
Presentations from ISPOR and HTAi 2018Thursday, 12 July 2018OHE staff recently attended ISPOR and HTAi international conferences. In this blog post, we share a selection of our presentations. Read more »
